A Phase IV, Prospective, Single-Arm, Open-Label Study to measure Outcomes in Patients with Pulmonary Arterial Hypertension not on active treatment
02/25/2015 - 02/24/2020 (PI)Bayer HealthCare Pharmaceuticals
A Phase 2, Dose-ranging, Randomized, Double-blind, Placebo Controlled Study of GS-4997 in subjects with Pulmonary Arterial Hypertension
12/22/2014 - 12/21/2019 (PI)Gilead Sciences, Inc.
A 24-Week Pilot Study to Investigate Changes in Proteomic and Genomic Profiles in Patients with Pulmonary Arterial Hypertension Associated with Scleroderma Treated with Macitentan-PIONEER 2
11/05/2015 - 11/04/2019 (PI)Actelion Pharmaceuticals, Ltd.
REPAIR: Right Ventricular Remodeling in Pulmonary Arterial Hypertension
07/15/2015 - 07/14/2019 (PI)Actelion Pharmaceuticals, Ltd.
Uptravi® (SelexiPag): tHe usErs dRug rEgistry
09/01/2016 - 08/31/2018 (PI)Actelion Pharmaceuticals US, Inc.
A Prospective, multicenter, double-blind, randomized, placebo-controlled, parallel-group, 12-week study to evaluate the safety and tolerability of macitentan in subjects with combined pre- and post-ca
06/11/2014 - 06/06/2018 (PI)Actelion Clinical Operations, Inc.
A Phase 2, Placebo Controlled, Double-Blind, Randomized, Clinical Study to Determine Safety, Tolerability and Efficacy of Pulsed, Inhaled, Nitric Oxide (iNO) Versus Placebo as Add-On Therapy in Sympto
06/01/2012 - 05/31/2017 (PI)Ikaria
A multi-Center, Double Blind, Placebo-Controlled Phase 3 Study to Demonstrate the Efficacy and Safety of ACT-293987 in Patients with Pulmonary Hypertension
04/01/2011 - 05/31/2017 (PI)Actelion Pharmaceuticals, Ltd.
EPOCH Treatment Satisfaction Qualitative Study (EPOCH-TSQS)
03/10/2015 - 03/09/2017 (PI)Actelion Pharmaceuticals, Ltd.
A multi-center, open-label, single-arm, Phase 3b study of macitentan in patients with Pulmonary Arterial Hypertension to psychometrically validate the PAH-SYMPACT instrument
10/17/2013 - 01/01/2017 (PI)Actelion Pharmaceuticals, Ltd.
Showing 10 of 41 results.
Show All Results